ZTS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 25.08% compared to Zoetis's net margin of 32.59%. Zoetis's return on equity of 49.71% beat Eli Lilly and's return on equity of 80.24%.

Zoetis has a consensus price target of $198.31, signalling upside risk potential of 29.22%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that Zoetis has higher upside potential than Eli Lilly and, analysts believe Zoetis is more attractive than Eli Lilly and.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.22%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zoetis's net income of $581M is lower than Eli Lilly and's net income of $4.4B. Notably, Zoetis's price-to-earnings ratio is 28.06x while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.54x versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 25.08% compared to Zoetis's net margin of 32.71%. Zoetis's return on equity of 49.71% beat Merck &'s return on equity of 40.25%.

Zoetis has a consensus price target of $198.31, signalling upside risk potential of 29.22%. On the other hand Merck & has an analysts' consensus of $108.19 which suggests that it could grow by 30.76%. Given that Merck & has higher upside potential than Zoetis, analysts believe Merck & is more attractive than Zoetis.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.22%. Merck & offers a yield of 3.82% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Merck & quarterly revenues of $15.5B. Zoetis's net income of $581M is lower than Merck &'s net income of $5.1B. Notably, Zoetis's price-to-earnings ratio is 28.06x while Merck &'s PE ratio is 12.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.54x versus 3.28x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 25.08% compared to Zoetis's net margin of 2.31%. Zoetis's return on equity of 49.71% beat Pfizer's return on equity of 8.91%.

Zoetis has a consensus price target of $198.31, signalling upside risk potential of 29.22%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 28.4%. Given that Zoetis has higher upside potential than Pfizer, analysts believe Zoetis is more attractive than Pfizer.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.22%. Pfizer offers a yield of 7.37% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.3B, which are smaller than Pfizer quarterly revenues of $17.8B. Zoetis's net income of $581M is higher than Pfizer's net income of $410M. Notably, Zoetis's price-to-earnings ratio is 28.06x while Pfizer's PE ratio is 16.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.54x versus 2.05x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 25.08% compared to Zoetis's net margin of 8.8%. Zoetis's return on equity of 49.71% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Zoetis has a consensus price target of $198.31, signalling upside risk potential of 29.22%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 20.42%. Given that Zoetis has higher upside potential than Supernus Pharmaceuticals, analysts believe Zoetis is more attractive than Supernus Pharmaceuticals.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.882%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.22%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Zoetis's net income of $581M is higher than Supernus Pharmaceuticals's net income of $15.3M. Notably, Zoetis's price-to-earnings ratio is 28.06x while Supernus Pharmaceuticals's PE ratio is 24.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.54x versus 2.72x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.